priors.science/reviews/bladder-cancer-pharmacotherapy

Bladder Cancer Pharmacotherapy

The current evidence on 19 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

19claims tracked
2 May 2026latest evidence review
Weeklyre-scored against new papers
8 Established · 4 Likely · 4 Uncertain · 3 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableIntravesical BCG immunotherapy is superior to intravesical chemotherapy for reducing disease progression and recurrence in high-risk non-muscle-invasive bladder cancer.NmibcEstablished96%
StableEnfortumab vedotin combined with pembrolizumab is superior to platinum-based chemotherapy as first-line treatment for advanced urothelial carcinoma.First Line AdvancedEstablished94%
StableNeoadjuvant cisplatin-based chemotherapy before radical cystectomy improves overall survival in muscle-invasive bladder cancer.Mibc PerioperativeEstablished94%
StablePembrolizumab prolongs overall survival compared with chemotherapy as second-line treatment for advanced urothelial carcinoma after platinum failure.Salvage AdvancedEstablished91%
StableFGFR2/3 genomic alterations reliably predict clinical benefit from erdafitinib in advanced urothelial carcinoma.Biomarker TargetedEstablished89%
StableEnfortumab vedotin monotherapy improves overall survival compared with chemotherapy in advanced urothelial carcinoma after platinum and immune checkpoint inhibitor failure.Salvage AdvancedEstablished89%
StableAvelumab maintenance therapy prolongs overall survival in patients with advanced urothelial carcinoma that has not progressed after platinum-based chemotherapy.First Line AdvancedEstablished88%
StableErdafitinib improves overall survival compared with chemotherapy in FGFR2/3-altered advanced urothelial carcinoma after platinum and immune checkpoint inhibitor failure.Salvage AdvancedEstablished88%
StablePerioperative durvalumab added to neoadjuvant gemcitabine-cisplatin chemotherapy improves event-free survival in muscle-invasive bladder cancer.Mibc PerioperativeLikely83%
StableOral erdafitinib reduces recurrence compared with intravesical chemotherapy in patients with BCG-unresponsive, FGFR2/3-altered high-risk non-muscle-invasive bladder cancer.NmibcLikely83%
StableAdjuvant nivolumab after radical cystectomy reduces disease recurrence in patients with muscle-invasive urothelial carcinoma at high risk of relapse.Mibc PerioperativeLikely75%
StableNadofaragene firadenovec gene therapy achieves durable complete responses as an intravesical treatment for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.NmibcLikely70%
StablePembrolizumab achieves durable complete responses in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer containing carcinoma in situ.NmibcUncertain64%
StableDose-dense MVAC is superior to gemcitabine-cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer based on pathological response and survival outcomes.Mibc PerioperativeUncertain55%
StableTumour mutational burden (TMB-high ≥10 mut/Mb) predicts pembrolizumab benefit in advanced urothelial carcinoma.Biomarker TargetedUncertain52%
StablePembrolizumab monotherapy provides durable responses as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma.First Line AdvancedUncertain49%
StablePD-L1 expression (CPS or IC scoring) is a reliable predictive biomarker for immune checkpoint inhibitor benefit in advanced urothelial carcinoma.Biomarker TargetedDoubtful35%
StableSacituzumab govitecan post-platinumSalvage AdvancedDoubtful29%
StableAtezolizumab 1L meaningful benefitFirst Line AdvancedDoubtful16%
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic